| Literature DB >> 20219409 |
Marianne M Stanford1, John C Bell, Markus J V Vähä-Koskela.
Abstract
The use of viruses as targeted cancer therapy has shown significant promise, and the list of oncolytic viruses continue to grow. The interest in unexplored viruses as oncolytic agents is a natural corollary to the successes and challenges of those already being examined in the clinical setting. Are these 'new' viruses any more effective than their predecessors? What are the benefits of refining current clinical candidates compared to searching for new ones? This review briefly describes some of these novel oncolytic viruses. It also examines the issues that arise in comparing them to each other. We believe that the viral mechanism of action is a key factor to success and suggest guidelines by which all oncolytic virus candidates could be evaluated. Crown Copyright 2010. Published by Elsevier Ltd. All rights reserved.Entities:
Mesh：
Year: 2010 PMID： 20219409 DOI： 10.1016/j.cytogfr.2010.02.012
Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN： 1359-6101 Impact factor: 7.638